About NGM Biopharmaceuticals
NGM Biopharmaceuticals is a company based in San Francisco (United States) founded in 2007.. NGM Biopharmaceuticals has raised $358.87 million across 7 funding rounds from investors including Merck, The Column Group and Prospect Venture Partners. NGM Biopharmaceuticals offers products and services including NGM120 and Pipeline Drugs. NGM Biopharmaceuticals operates in a competitive market with competitors including Rhythm Pharmaceuticals, MannKind Corp, Nimbus Therapeutics, Corcept and Altimmune, among others.
- Headquarter San Francisco, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ngm Biopharmaceuticals, Inc.
-
Annual Revenue
$4.42 M (USD)-92.26as on Dec 31, 2023
-
Net Profit
$-142.53 M (USD)15.13as on Dec 31, 2023
-
EBITDA
$-144.49 M (USD)12.68as on Dec 31, 2023
-
Total Equity Funding
$358.87 M (USD)
in 7 rounds
-
Latest Funding Round
$106 M (USD), Series D
Mar 25, 2015
-
Investors
Merck
& 5 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of NGM Biopharmaceuticals
NGM Biopharmaceuticals is a publicly listed company on the GETTEX with ticker symbol 0IK in Germany, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of NGM Biopharmaceuticals
NGM Biopharmaceuticals offers a comprehensive portfolio of products and services, including NGM120 and Pipeline Drugs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Drug candidate for treating Hyperemesis Gravidarum in clinical trials
In-house developed drugs addressing various global diseases
Unlock access to complete
Unlock access to complete
Funding Insights of NGM Biopharmaceuticals
NGM Biopharmaceuticals has successfully raised a total of $358.87M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $106 million completed in March 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series D — $106.0M
-
First Round
First Round
(11 Feb 2008)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2015 | Amount | Series D - NGM Biopharmaceuticals | Valuation | Merck |
|
| Feb, 2015 | Amount | Series D - NGM Biopharmaceuticals | Valuation | Prospect Venture Partners , TCG | |
| Jul, 2013 | Amount | Series C - NGM Biopharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in NGM Biopharmaceuticals
NGM Biopharmaceuticals has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, The Column Group and Prospect Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in US life sciences and healthtech firms.
|
Founded Year | Domain | Location | |
|
Early-stage investments in US life science startups are focused on.
|
Founded Year | Domain | Location | |
|
Topspin Consumer Partners is engaged in private equity investments focused on consumer brands.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by NGM Biopharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - NGM Biopharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ngm Biopharmaceuticals Comparisons
Competitors of NGM Biopharmaceuticals
NGM Biopharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rhythm Pharmaceuticals, MannKind Corp, Nimbus Therapeutics, Corcept and Altimmune, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of small-molecule drugs
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of cortisol modulators for the treatment of various diseases
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases and solid tumors are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ngm Biopharmaceuticals
Frequently Asked Questions about NGM Biopharmaceuticals
When was NGM Biopharmaceuticals founded?
NGM Biopharmaceuticals was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Where is NGM Biopharmaceuticals located?
NGM Biopharmaceuticals is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of NGM Biopharmaceuticals?
David J Woodhouse is the current CEO of NGM Biopharmaceuticals.
Is NGM Biopharmaceuticals a funded company?
NGM Biopharmaceuticals is a funded company, having raised a total of $358.87M across 7 funding rounds to date. The company's 1st funding round was a Series C of $50M, raised on Feb 11, 2008.
What is the annual revenue of NGM Biopharmaceuticals?
Annual revenue of NGM Biopharmaceuticals is $4.42M as on Dec 31, 2023.
What does NGM Biopharmaceuticals do?
NGM Biopharmaceuticals was founded in 2007 and is based in San Francisco, United States. Biologics are developed in the biopharmaceutical sector for treating cardio-metabolic and liver diseases. Operations focus on drug candidates such as NGM282, which targets bile acid-related conditions and non-alcoholic steatohepatitis. Additional candidates address Type 2 diabetes and obesity. Leadership is provided by CEO David J. Woodhouse.
Who are the top competitors of NGM Biopharmaceuticals?
NGM Biopharmaceuticals's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.
What products or services does NGM Biopharmaceuticals offer?
NGM Biopharmaceuticals offers NGM120 and Pipeline Drugs.
Is NGM Biopharmaceuticals publicly traded?
Yes, NGM Biopharmaceuticals is publicly traded on GETTEX under the ticker symbol 0IK.
Who are NGM Biopharmaceuticals's investors?
NGM Biopharmaceuticals has 6 investors. Key investors include Merck, The Column Group, Prospect Venture Partners, Topspin Consumer Partners, and Tichenor Ventures.
What is NGM Biopharmaceuticals's ticker symbol?
The ticker symbol of NGM Biopharmaceuticals is 0IK on GETTEX.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.